Literature DB >> 27371869

Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients.

Loralie J Langman1, Lior Nesher2, Dimpy P Shah3, Jacques M Azzi3, Elizabeth J Shpall4, Katy Rezvani4, John L Black5, Roy F Chemaly3.   

Abstract

As part of a pharmacogenetic study, paired blood and oral fluid samples were tested for the IL28B polymorphism (rs12979860) before and after hematopoietic cell transplantation (HCT) to evaluate changes in the genotype and investigate the utility of genotyping in oral fluid in HCT recipients. In 54 patients with leukemia >18 years of age, samples were collected approximately 7 days before HCT and 60 days after HCT. IL28B polymorphism testing was performed using real-time PCR with allele-specific probes. Twenty-four patients had the same genotype as their donors. In 30 patients, the genotype was different from that of the donor. In the oral fluid samples, 4 retained the recipient's genotype, and 18 had a genotype that matched that of the donor. In the remaining 8 patients, the results could not be characterized and appeared to be a combination of both, suggesting mixed proportions of donor and recipient cells. The assumption was that the sloughed epithelial cells of the mouth are of recipient origin. However, oral fluid is a mixture that contains varying numbers of cells of the recipient and immunomodulatory cells from the donor. Therefore, the use of oral fluid after HCT for clinical pharmacogenetics purposes needs further investigation.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27371869      PMCID: PMC5397711          DOI: 10.1016/j.jmoldx.2016.03.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  9 in total

1.  Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants.

Authors:  C Thiede; G Prange-Krex; J Freiberg-Richter; M Bornhäuser; G Ehninger
Journal:  Bone Marrow Transplant       Date:  2000-03       Impact factor: 5.483

2.  Allele-specific PCR for determination of IL28B genotype.

Authors:  Linda Cook; Kurt Diem; Woo Kim; John D Scott; Keith R Jerome
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation.

Authors:  G Endler; H Greinix; K Winkler; G Mitterbauer; C Mannhalter
Journal:  Bone Marrow Transplant       Date:  1999-07       Impact factor: 5.483

4.  Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells.

Authors:  Zhiwei Yin; Jihong Dai; Jing Deng; Faruk Sheikh; Mahwish Natalia; Tiffany Shih; Anita Lewis-Antes; Sheela B Amrute; Ursula Garrigues; Sean Doyle; Raymond P Donnelly; Sergei V Kotenko; Patricia Fitzgerald-Bocarsly
Journal:  J Immunol       Date:  2012-08-13       Impact factor: 5.422

Review 5.  Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.

Authors:  Moustapha Hassan; Borje S Andersson
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

6.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

Review 7.  Pharmacogenetics of antiretroviral therapy.

Authors:  Pablo Barreiro; José Vicente Fernández-Montero; Carmen de Mendoza; Pablo Labarga; Vincent Soriano
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-06-18       Impact factor: 4.481

8.  Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients.

Authors:  Dayana Bravo; Carlos Solano; Estela Giménez; María José Remigia; Isabel Corrales; Paula Amat; David Navarro
Journal:  J Med Virol       Date:  2013-12-27       Impact factor: 2.327

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

  9 in total
  2 in total

Review 1.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

Review 2.  Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.

Authors:  Gopi Suresh Oggu; Shyama Sasikumar; Nirosha Reddy; Kranthi Kiran Reddy Ella; Ch Mohan Rao; Kiran Kumar Bokara
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 6.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.